Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care

Cancer Journal

Volumn 7, Issue 2, 2001, Pages 112-120

  Gitlitz, B J ^a   Hoffman, D M J ^a   Moldawer, N ^a   Belldegrum, A ^a   Figlin, R A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL;

ADULT; AGED; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITAL UNITS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035045521     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cancer statistics, 2000
2. Metastatic renal-cell carcinoma: What causes occasional dramatic regressions?
3. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma
4. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
5. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group study
6. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma
7. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
8. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
9. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients
10. 13-cis-retinoic acid, IFN-α, IL-2, and chemotherapy in advanced renal cell carcinoma: Results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Immunotherapy Group (DGCIN)
11. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor
12. Renal cell carcinoma: Current status and future plans
13. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
14. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2
15. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2